HRP20050699A2 - Pde4 inhibitors for the treatment of neoplasms of lymphoid cells - Google Patents

Pde4 inhibitors for the treatment of neoplasms of lymphoid cells

Info

Publication number
HRP20050699A2
HRP20050699A2 HR20050699A HRP20050699A HRP20050699A2 HR P20050699 A2 HRP20050699 A2 HR P20050699A2 HR 20050699 A HR20050699 A HR 20050699A HR P20050699 A HRP20050699 A HR P20050699A HR P20050699 A2 HRP20050699 A2 HR P20050699A2
Authority
HR
Croatia
Prior art keywords
treatment
pde4 inhibitors
neoplasms
lymphoid cells
campa
Prior art date
Application number
HR20050699A
Other languages
English (en)
Inventor
Braunger J�rgen
Schudt Christian
Hatzelmann Armin
Tenor Hermann
Gekeler Volker
Sanders Karl
Garattini Enrico
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of HRP20050699A2 publication Critical patent/HRP20050699A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Izum se odnosi na uporabu određenih PDE4 inhibitora samih ili u kombinaciji sa jednim ili više agensa koji induciraju diferencijaciju i/ili agensom koji je učinkovit u podizanju intracelularne koncentracije cAMPa ili stabilni analog cAMPa u pripravljanju farmaceutskog pripravka za liječenje neoplazmi limfatičnih stanica.
HR20050699A 2003-01-14 2005-08-03 Pde4 inhibitors for the treatment of neoplasms of lymphoid cells HRP20050699A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03000787 2003-01-14
PCT/EP2004/000196 WO2004062671A2 (en) 2003-01-14 2004-01-14 Pde4 inhibitors for the treatment of neoplasms of lymphoid cells

Publications (1)

Publication Number Publication Date
HRP20050699A2 true HRP20050699A2 (en) 2006-11-30

Family

ID=32695591

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050699A HRP20050699A2 (en) 2003-01-14 2005-08-03 Pde4 inhibitors for the treatment of neoplasms of lymphoid cells

Country Status (10)

Country Link
US (1) US20060148804A1 (hr)
EP (1) EP1587512A2 (hr)
JP (1) JP2006515367A (hr)
AU (1) AU2004204355B2 (hr)
CA (1) CA2512819A1 (hr)
HR (1) HRP20050699A2 (hr)
IS (1) IS7970A (hr)
PL (1) PL378247A1 (hr)
RS (1) RS20050523A (hr)
WO (1) WO2004062671A2 (hr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
AU2008276451A1 (en) * 2007-07-17 2009-01-22 Zalicus Inc. Treatments of B-cell proliferative disorders
US20090047243A1 (en) * 2007-07-17 2009-02-19 Richard Rickles Combinations for the treatment of b-cell proliferative disorders
WO2009147169A1 (en) * 2008-06-03 2009-12-10 Universite Paris Diderot-Paris 7 Pharmaceuticl compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
MX2013014888A (es) * 2011-06-17 2014-02-27 Takeda Gmbh Novedosos derivados de ftalazinona-pirrolopirimidinacarboxamida.
AR089232A1 (es) * 2011-12-16 2014-08-06 Chiesi Farma Spa Potenciacion inducida por inhibidores de pde4 en el tratamiento de la leucemia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6047099A (en) * 1998-09-24 2000-04-10 Boston Medical Center Corporation Compositions and methods for the treatment of chronic lymphocytic leukemia
US6624154B1 (en) * 1999-04-23 2003-09-23 Bristol-Myers Squibb Company Compositions and methods for treatment of hyperproliferative diseases
US6232121B1 (en) * 1999-06-03 2001-05-15 Hugh S. Keeping Methods for the production of biologically active agents contained in an extracellular matrix
AU5195599A (en) * 1999-08-10 2001-03-13 Wago Co., Ltd. Anchor bolt and method of manufacturing the anchor bolt
EP2193808A1 (en) * 1999-08-21 2010-06-09 Nycomed GmbH Synergistic combination
CN1146562C (zh) * 1999-10-25 2004-04-21 奥坦纳医药公司 作为pde4抑制剂的四氢噻喃2,3-二氮杂萘酮类衍生物
ES2267778T3 (es) * 2000-06-06 2007-03-16 Glaxo Group Limited Composicion para el tratamiento del cancer, que contiene un agente anti-neoplastico y un inhibidor de pde4.
EE05386B1 (et) * 2001-02-15 2011-02-15 ALTANA�Pharma�AG Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim
GB0111497D0 (en) * 2001-05-11 2001-07-04 Medical Res Council Therapeutic methods

Also Published As

Publication number Publication date
WO2004062671A3 (en) 2005-01-27
CA2512819A1 (en) 2004-07-29
IS7970A (is) 2005-08-05
RS20050523A (en) 2007-09-21
AU2004204355A1 (en) 2004-07-29
US20060148804A1 (en) 2006-07-06
JP2006515367A (ja) 2006-05-25
WO2004062671A2 (en) 2004-07-29
AU2004204355B2 (en) 2009-12-17
PL378247A1 (pl) 2006-03-20
EP1587512A2 (en) 2005-10-26

Similar Documents

Publication Publication Date Title
HRP20050699A2 (en) Pde4 inhibitors for the treatment of neoplasms of lymphoid cells
ATE461171T1 (de) Neue mandelsäurederivate und deren verwendung als thrombininhibitoren
HRP20050123B1 (hr) Kompozicija i antivirusna aktivnost supstituiranih azaindoloksooctenih piperazin derivata
PA8657201A1 (es) Compuestos de 3h-oxazolo y 3h-tiazolo [4, 5-d] pirimidin-2-ona 3, 5-disustituida y 3, 5, 7 - trisustituida y profarmacos de los mismos
ATE527242T1 (de) Piperazin derivate und deren anwendung als therapeutische wirkstoffe
ATE411992T1 (de) Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
DE60320940D1 (de) Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
DE602005015833D1 (de) Imidazopyridin- und imidazopyrimidin-derivate als antibakterielle mittel
UY29727A1 (es) 7-aza-indazoles sustituidos, composiciones que les contienen, procedimientos de fabricación y utilización.
ATE498395T1 (de) Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
DE60315303D1 (de) Zweiphasige zusammensetzung enthaltend polydextrose und saccharose
BRPI0513880A (pt) método para a polarização nuclear dinámica de um composto, radicais, uso de radicais, e, composição
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
SG145695A1 (en) Pyridyl derivatives and their use as therapeutic agents
BRPI0719195B8 (pt) inibidores de quinase, seus usos, e composição farmacêutica
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
DE602005015486D1 (de) Esterderivate von ascorbinsäure und 2-ketosäuresacchariden
AR057474A1 (es) Composiciones de donepezil gelificado y metodos para la fabricacion y utilizacion de las mismas
TR200201246T2 (tr) Hidroksieikosatetraenoik asit türevlerini ihtiva eden bileşimler ve göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri
UY29236A1 (es) 2-alcoxi-3,4,5-trihidroxi-alquilamidas. su preparación, composiciones que las contienen y su utilización.
DE60127970D1 (de) Zusammensetzung, welche ein antifolate und ein methylmalonsäuresenkendes mittel enthält
BR0312451A (pt) Composição detergente
ITMI20051417A1 (it) Formulazione topica in forma di gel contenente come ingredienti attivi ciclovit e lidocaina
ATE443512T1 (de) Pharmazeutische zusammensetzung von piperazinderivaten
SE0402284D0 (sv) New heterocyclic amides

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: NYCOMED GMBH, DE

ODRP Renewal fee for the maintenance of a patent

Payment date: 20090113

Year of fee payment: 7

OBST Application withdrawn